Drug Trial Radar · NCT04772079
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
153
Planned (sponsor's estimate)
Start
Mar 23, 2021
Primary completion
Jan 1, 2029
Study completion Sep 8, 2033
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Feb 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in children and adolescent participants with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in children and adolescent participants with psoriasis who have completed Parts A or B of the study.
Conditions
- Plaque Psoriasis
Interventions
DeucravacitinibDrug
Specified dose on specified days
Placebo matching deucravacitinibOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Observed average concentration at steady state for deucravacitinib at Week 2Time frame: Week 2
- Maximum observed plasma concentration at steady state for deucravacitinib at Week 2Time frame: Week 2
- Trough observed plasma concentration for deucravacitinib at Week 2Time frame: Week 2
- Proportion of subjects with at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16Time frame: Week 16
- Proportion of subjects with an static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16Time frame: Week 16
- Incidence of Adverse Events (AEs)Time frame: Up to 316 weeks
- Incidence of serious adverse events (SAEs)Time frame: Up to 316 weeks
- Monitoring of growth: Body weightTime frame: Up to 316 weeks
- Monitoring of growth: HeightTime frame: Up to 316 weeks
- Monitoring of growth: Tanner staging (sexual maturation)Time frame: Up to 316 weeks
Locations
65 sites in 13 countries. Site status is shown where the registry gives one.
CONEXA Investigacion Clinica S.A.
Buenos Aires, Argentina · Recruiting
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires
CABA, Argentina · Recruiting
Consultora Integral de Salud
Córdoba, Argentina · Recruiting
Instituto de Neumonologia Y Dermatologia
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Psoriahue
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Local Institution - 0020
Darlinghurst, New South Wales, Australia · Active not recruiting
Local Institution - 0002
Westmead, New South Wales, Australia · Withdrawn
Queensland Children's Hospital
Brisbane, Queensland, Australia · Recruiting
Local Institution - 0003
Woolloongabba, Queensland, Australia · Completed
Monash Health
Clayton, Victoria, Australia · Recruiting
Local Institution - 0001
Melbourne, Victoria, Australia · Completed
Local Institution - 0083
Rio de Janeiro, Brazil · Withdrawn
Local Institution - 0067
São Paulo, Brazil · Withdrawn
Centro de Pesquisas da Clínica IBIS
Salvador, Estado de Bahia, Brazil · Recruiting
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) - HCFMRP
Ribeirão Preto, São Paulo, Brazil · Recruiting
Local Institution - 0010
Calgary, Alberta, Canada · Completed
Alberta Dermasurgery Centre
Edmonton, Alberta, Canada · Recruiting
Local Institution - 0039
Hamilton, Ontario, Canada · Withdrawn
Lynderm Research Inc.
Markham, Ontario, Canada · Recruiting
The Hospital for Sick Children
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier de Calais
Calais, France · Recruiting
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand-dermatology
Dijon, France · Recruiting
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet
Nice, France · Recruiting
Local Institution - 0021
Paris, France · Completed
Charité - Universitaetsmedizin Berlin - Campus Bejnamin Franklin
Berlin, Germany · Recruiting
Kath. Kinderkrankenhaus Wilhelmstift
Hamburg, Germany · Recruiting
Universitätsklinikum Münster
Münster, North Rhine-Westphalia, Germany · Recruiting
Universitätsmedizin Johannes Gutenberg Universität Mainz
Mainz, Rhineland-Palatinate, Germany · Recruiting
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Saxony, Germany · Recruiting
Nippon Life Hospital
Osaka, Japan · Recruiting
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan · Recruiting
Fukuoka University Hospital
Fukuoka, Jonan-Ku, Fukuoka, Japan · Recruiting
Local Institution - 0040
Isehara, Kanagawa, Japan · Withdrawn
Mie University Hospital
Tsu, Mie-ken, Japan · Recruiting
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan · Recruiting
Teikyo University Hospital
tabashi City, Tokyo, Japan · Recruiting
Arké SMO S.A de C.V
Veracruz, Mexico · Recruiting
Crea de Guadalajara
Guadalajara, Jalisco, Mexico · Recruiting
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.